Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China · Delayed Price · Currency is CNY 250.10
+2.79 (1.13%)
At close: May 21, 2026
SHA:688506 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,297 | -1,054 | 3,708 | -780.5 | -282.38 | -99.99 |
Depreciation & Amortization | 103.06 | 103.06 | 79.59 | 64.72 | 62.94 | 53.14 |
Other Amortization | 6.69 | 6.69 | 3.34 | 2.31 | 1.79 | 1.08 |
Loss (Gain) From Sale of Assets | -0 | -0 | 0 | -0.15 | 0.02 | -0.01 |
Asset Writedown & Restructuring Costs | 3.33 | 3.33 | 0.22 | 0.29 | 0.46 | 6.13 |
Loss (Gain) From Sale of Investments | -4.17 | -4.17 | -30.68 | -0 | - | -3.14 |
Provision & Write-off of Bad Debts | -1.65 | -1.65 | 0.58 | -6.65 | 7.58 | -3 |
Other Operating Activities | 109.14 | 118.02 | 73.65 | 40.74 | 27.79 | 9.45 |
Change in Accounts Receivable | -124.67 | -124.67 | 275.68 | 73.6 | -142.62 | 62.89 |
Change in Inventory | -10.82 | -10.82 | -42.14 | -52.56 | -23.96 | -22.22 |
Change in Accounts Payable | -32.25 | -32.25 | 70.92 | 35.92 | 107.12 | -121.61 |
Change in Other Net Operating Assets | 54.34 | 54.34 | 21.07 | -0.04 | 0.03 | -0.06 |
Operating Cash Flow | -1,050 | -798.4 | 4,059 | -615.35 | -258.65 | -135.03 |
Capital Expenditures | -324.5 | -263.81 | -83.86 | -81.94 | -34.56 | -44.6 |
Sale of Property, Plant & Equipment | 3.15 | 1.26 | 0.1 | 0.06 | 0.01 | 0.07 |
Investment in Securities | -2,037 | -2,037 | -2,512 | - | - | 197.2 |
Other Investing Activities | -1,817 | 0.48 | 30.68 | 0 | - | 3.48 |
Investing Cash Flow | -4,176 | -2,300 | -2,565 | -81.88 | -34.55 | 156.15 |
Long-Term Debt Issued | - | 2,404 | 1,904 | 447.7 | 467.54 | 302 |
Long-Term Debt Repaid | - | -888.94 | -572.18 | -312.94 | -220.82 | -184.21 |
Net Debt Issued (Repaid) | 1,334 | 1,515 | 1,332 | 134.76 | 246.72 | 117.79 |
Issuance of Common Stock | 3,732 | 3,732 | - | - | 907.47 | - |
Common Dividends Paid | -85.78 | -78.38 | -38.36 | -18.77 | -12.59 | -26.97 |
Other Financing Activities | -240.63 | -43.66 | -19.5 | -25.14 | -2.19 | -2.16 |
Financing Cash Flow | 4,740 | 5,125 | 1,274 | 90.84 | 1,139 | 88.66 |
Foreign Exchange Rate Adjustments | -244.73 | -92.74 | 49.19 | -2.62 | 0.26 | -0.76 |
Net Cash Flow | -731.17 | 1,934 | 2,816 | -609 | 846.47 | 109.01 |
Free Cash Flow | -1,375 | -1,062 | 3,975 | -697.29 | -293.21 | -179.63 |
Free Cash Flow Margin | -53.98% | -42.15% | 68.26% | -124.10% | -41.69% | -22.55% |
Free Cash Flow Per Share | -3.38 | -2.63 | 9.92 | -1.74 | -0.81 | -0.50 |
Cash Income Tax Paid | 264.12 | 264.12 | 428.2 | 48.98 | 36.6 | 101.05 |
Levered Free Cash Flow | -2,102 | -913.21 | 2,700 | -396 | -145.1 | -135.4 |
Unlevered Free Cash Flow | -2,043 | -860.04 | 2,726 | -380.58 | -131.05 | -129.97 |
Change in Working Capital | 29.95 | 29.95 | 224.46 | 63.88 | -76.86 | -98.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.